Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -48.96% | -9.66% | 36.16% | -2.44% | 19.38% |
| Total Depreciation and Amortization | -1.99% | -1.71% | -4.21% | 6.12% | 0.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.99% | 152.51% | -65.88% | 146.47% | -61.51% |
| Change in Net Operating Assets | 5,240.82% | 98.30% | -153.53% | -83.33% | 1,430.90% |
| Cash from Operations | -39.35% | 38.83% | -80.29% | -137.07% | 229.79% |
| Capital Expenditure | 53.33% | 89.51% | 90.19% | -840.65% | 93.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.19% | 125.36% | -1,356.13% | 114.26% | -1,337.90% |
| Cash from Investing | 17.28% | 125.25% | -2,160.02% | 108.67% | -506.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.93% | 146,745.10% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 83.22% | 31.72% | -28.46% | -30.32% | 6.72% |
| Cash from Financing | 24.03% | -111.37% | 870.77% | -29.53% | 6.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.86% | -148.82% | 141.07% | 18.75% | 37.76% |